Vericel Corp. (VCEL)

[realfast95]

On May 28, 2019, Daniel Orlando notified the Company of his intention to resign as the Company’s Chief Operating Officer in order to join a privately held biotechnology company as its Chief Executive Officer . The effective date of Mr. Orlando’s resignation is June 14, 2019.



(c)



On June 3, 2019, the Company appointed Michael Halpin, 58, as Chief Operating Officer of the Company, effective as of June 15, 2019. Mr. Halpin joined the Company on April 10, 2017 as Senior Vice President, Quality and Regulatory Affairs, where he was responsible for quality activities and regulatory strategy. From 2016 until joining the Company, Mr. Halpin served as Vice President, North American region regulatory head at Sanofi Genzyme. Prior to that, Mr. Halpin served as Vice President, Regulatory Affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Epicel ® and MACI ® . Prior to Genzyme, Mr. Halpin held a number of regulatory, quality and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard and Abiomed. Mr. Halpin received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.



There is no arrangement or understanding with any other person pursuant to which Mr. Halpin was appointed as the Chief Operating Officer, and there are no family relationships between Mr. Halpin and any director or executive officer of the Company. Additionally, there are no transactions involving Mr. Halpin that would be required to be reported under Item 404(a) of Regulation S-K.